Unfortunately, at present there are no standardized or regulatory-approved MRD assays for FLT3-mutated AML, which complicates efforts to evaluate and optimize FLT3 inhibitor strategies in the maintenance setting. This evidence concerns the gene FLT3 and acute myeloid leukemia.